drugset / Trial / NCT05206604
A First-in-human Study of Multiple Doses of Topically Administered PF-07295324 and PF-07259955
RandomizedSequentialTriple-blindTreatment
Summary
The purpose of the study is to evaluate the safety, (local and systemic) tolerability, and pharmacokinetics following multiple doses of topically applied, maximum feasible formulations of PF-07295324 (0.12% w/w) or PF-07259955 (2% w/w), on approximately 20% body surface area (BSA), in healthy adult participants.
Timeline
- Start
- 2022-02-09
- Primary completion
- 2022-08-12
- Completion
- 2022-08-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | PF-07259955 | Unknown | 2 % | Topical |
| Subject | PF-07295324 | Unknown | 0.12 % | Topical |
Indications
No indication recorded.